Tarsus Pharmaceuticals (TARS) Enterprise Value (2020 - 2026)

Tarsus Pharmaceuticals' Enterprise Value history runs 8 years deep, the most recent figure standing at -$102.2 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 74.95% year-over-year to -$102.2 million; the TTM figure through Mar 2026 stood at -$102.2 million (up 74.95% YoY), while the FY2025 annual figure was -$184.2 million, up 36.78% from the prior year.
• Enterprise Value for Q1 2026 stood at -$102.2 million, up from -$184.2 million in the prior quarter.
• The five-year high for Enterprise Value was -$102.2 million in Q1 2026, with the low at -$407.9 million in Q1 2025.
• The 5-year median for Enterprise Value is -$245.4 million (2022), against an average of -$260.3 million.
• The sharpest annual moves came in 2024 and 2026: Enterprise Value tumbled 81.55% in 2024, then surged 74.95% in 2026.
• Tarsus Pharmaceuticals' Enterprise Value stood at -$217.0 million in 2022, then dropped by 4.8% to -$227.4 million in 2023, then retreated by 28.11% to -$291.4 million in 2024, then soared by 36.78% to -$184.2 million in 2025, then surged by 44.52% to -$102.2 million in 2026.
• Business Quant data shows TARS's Enterprise Value at -$102.2 million in Q1 2026, -$184.2 million in Q4 2025, and -$401.8 million in Q3 2025.